Elvitegravir-d8
Product Specifications
UNSPSC Description
Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
Target Antigen
HIV; HIV Integrase; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection;Metabolic Enzyme/Protease;Others
Applications
COVID-19-anti-virus
Field of Research
Infection
Solubility
10 mM in DMSO
Smiles
OCC(N1C2=CC(OC)=C(CC3=C(C(Cl)=CC=C3)F)C=C2C(C(C(O)=O)=C1)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H]
Molecular Weight
455.93
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
